Table 8 Baseline viral hepatitis serology, safety population
Patients n/N (%) | |||
|---|---|---|---|
ASAQ | AL | ||
Study-T (>5 years) | N = 496 | N = 502 | Total |
HBV sAg positive | 73/457 (15.9) | 70/467 (14.9) | 143/924 (15.5) |
HBV anti-HBVc positive # | 4/73 (5.5) | 2/70 (2.8) | 6/143 (4.2) |
HCV antibody positive | 18/455 (4.0) | 19/466(4.1) | 37/921 (4.0) |
HEV anti-IgM positive* | 0/33 (0) | 0/34(0) | 0/67 (0) |
ASAQ | AL | ||
Study-E (6-59 months) | N = 149 | N = 150 | Total |
HBV sAg positive | 18/148 (12.1) | 18/150 (12.0) | 36/298 (12.1) |
HBV anti-HBVc positive # | 1/18 (5.5) | 1/18 (5.5) | 2/36 (5.5) |
HCV antibody positive | 7/147 (4.8) | 4/148 (2.7) | 11/295 (3.7) |
HEV anti-IgM positive* | 0/5 (0) | 0/7 (0) | 0/12 (0) |